Risk of cardiovascular morbidity with risperidone or paliperidone treatment: Analysis of 64 randomized, double-blind trials

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 157-161

  Gopal, Srihari ^a   Hough, David ^a,b   Karcher, Keith ^a   Nuamah, Isaac ^a   Palumbo, Joseph ^a,c   Berlin, Jesse A ^a   Baseman, Alan ^a   Xu, Yimei ^a   Kent, Justine ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular; morbidity; paliperidone; risperidone; sudden death

Indexed keywords

HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CONVULSION; DATA BASE; DOUBLE BLIND PROCEDURE; DRUG INFORMATION; DRUG SAFETY; DYSARTHRIA; ELECTROCARDIOGRAM; EMBOLISM; FAINTNESS; HEART FAILURE; HEART PALPITATION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; TACHYCARDIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DRUG LABELING; HUMANS; INCIDENCE; ISOXAZOLES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISPERIDONE;

EID: 84874942620     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318283983f     Document Type: Article

References (23)

1. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53. (Pubitemid 41587462)
2. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164:1293-1297. (Pubitemid 38828879)
3. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. 2003;107:85-95. (Pubitemid 36164475)
4. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
5. Medical Dictionary for Regulatory Activities. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 11.1. MedDRA Maintenance and Support Services Organization, Chantilly, VA. Available at: http://www.meddramsso.com; September 2008.
6. van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558-567.
7. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237-240.
8. Agresti A. Categorical Data Analysis. New York, NY: JohnWiley; 1990.
9. Report of CIOMS Working Groups III and V: Guidelines for Preparing Core Clinical-Safety Information on Drugs. 2nd ed. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS); 1999. Available at: https://apps.who.int/dsa/cat98/zcioms8.htm.
10. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257-268. (Pubitemid 23294526)
11. Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20(4):380-384. (Pubitemid 28359985)
12. Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 2005;28:35-51.
13. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219-233. (Pubitemid 30625285)
14. Gluais P, Bastide M, Caron J, et al. Risperidone prolongs cardiac action potential through reduction of K+ currents in rabbit myocytes. Eur J Pharmacol. 2002;444:123-132. (Pubitemid 34626829)
15. Titier K, Deridet E, Moore N. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone. Toxicol Appl Pharmacol. 2002;180:145-149. (Pubitemid 34478557)
16. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62-69. (Pubitemid 38134167)
17. Hough DW, Natarajan J, Vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:25-34.
18. Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20:243-251. (Pubitemid 41192144)
19. Vargas HM. A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window. Br J Pharmacol. 2010;161:1441-1443.
20. Axelsson S, Hagg S, Eriksson AC, et al. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol. 2007;34:775-780. (Pubitemid 47013497)
21. Every NR, Parsons L, Hlatky MA, et al. Use and accuracy of state death certificates for classification of sudden cardiac deaths in high-risk populations. Am Heart J. 1997;134:1129-1132. (Pubitemid 28040204)
22. Iribarren C, Crow RS, Hannan PJ, et al. Validation of death certificate diagnosis of out-of-hospital sudden cardiac death. Am J Cardiol. 1998;82:50-53. (Pubitemid 28322034)
23. Allebeck P, Varla A, Wistedt B. Suicide and violent death among patients with schizophrenia. Acta Psychiatr Scand. 1986;74:43-49. (Pubitemid 16061286)